Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials.

Angelo AntoniniDaniele BraviMichele SandreLuigi Bubacco

Published in: Expert opinion on investigational drugs (2020)

The efficacy of passive and active immunotherapies is inadequately evaluated in ongoing clinical trials where participating patients have various progression rates, genetic backgrounds, and clinical phenotypes. Future disease-modifying studies can overcome these limitations by enrolling patients based on progression pathways and genotypic contribution to disease manifestations.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
randomized controlled trial
gene expression
open label
patient reported
copy number